Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study.

Saved in:
Bibliographic Details
Title: Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study.
Authors: Robak T; a Copernicus Memorial Hospital , Medical University of Lodz , Lodz , Poland., Huang H; b Sun Yat-sen University Cancer Center , Guangzhou , Guangdong , China., Jin J; c The First Affiliated Hospital of Zhejiang University College of Medicine , Hangzhou , Zhejiang , China., Zhu J; d Beijing Cancer Hospital , Beijing , China., Liu T; e West China Hospital of Sichuan University , Chengdu , Sichuan , China., Samoilova O; f Nizhniy Novgorod Region Clinical Hospital , Nizhniy Novgorod , Russian Federation., Pylypenko H; g Cherkassy Regional Oncology Dispensary , Cherkassy , Ukraine., Verhoef G; h University Hospital Leuven , Leuven , Belgium., Siritanaratkul N; i Siriraj Hospital , Mahidol University , Bangkok , Thailand., Osmanov E; j Cancer Research Center RAMS - N.N. Blokhin Academy of Medical Science , Moscow , Russian Federation., Pereira J; k Hospital das Clinicas da Faculdade de Medicina da USP , São Paolo , Brazil., Mayer J; l Faculty Hospital Brno , Brno , Czech Republic., Hong X; m Fudan University Shanghai Cancer Center , Shanghai , China., Okamoto R; n Department of Chemotherapy , Tokyo Metropolitan Cancer and Infectious Diseases Center , Komagome Hospital , Japan., Pei L; o Janssen Research and Development, LLC , Raritan , NJ , USA., Rooney B; p Janssen Research & Development , High Wycombe , Buckinghamshire , UK., van de Velde H; q Millennium Pharmaceuticals, Inc. , Cambridge , MA , USA , a wholly owned subsidiary of Takeda Pharmaceutical Company Limited., Cavalli F; r Oncology Institute of Southern Switzerland, Ospedale San Giovanni , Bellinzona , Ticino , Switzerland.
Source: Leukemia & lymphoma [Leuk Lymphoma] 2019 Jan; Vol. 60 (1), pp. 172-179. Date of Electronic Publication: 2017 Jun 05.
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 28583031
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study<superscript>.</superscript>
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Robak+T%22">Robak T</searchLink>; a Copernicus Memorial Hospital , Medical University of Lodz , Lodz , Poland.<br /><searchLink fieldCode="AU" term="%22Huang+H%22">Huang H</searchLink>; b Sun Yat-sen University Cancer Center , Guangzhou , Guangdong , China.<br /><searchLink fieldCode="AU" term="%22Jin+J%22">Jin J</searchLink>; c The First Affiliated Hospital of Zhejiang University College of Medicine , Hangzhou , Zhejiang , China.<br /><searchLink fieldCode="AU" term="%22Zhu+J%22">Zhu J</searchLink>; d Beijing Cancer Hospital , Beijing , China.<br /><searchLink fieldCode="AU" term="%22Liu+T%22">Liu T</searchLink>; e West China Hospital of Sichuan University , Chengdu , Sichuan , China.<br /><searchLink fieldCode="AU" term="%22Samoilova+O%22">Samoilova O</searchLink>; f Nizhniy Novgorod Region Clinical Hospital , Nizhniy Novgorod , Russian Federation.<br /><searchLink fieldCode="AU" term="%22Pylypenko+H%22">Pylypenko H</searchLink>; g Cherkassy Regional Oncology Dispensary , Cherkassy , Ukraine.<br /><searchLink fieldCode="AU" term="%22Verhoef+G%22">Verhoef G</searchLink>; h University Hospital Leuven , Leuven , Belgium.<br /><searchLink fieldCode="AU" term="%22Siritanaratkul+N%22">Siritanaratkul N</searchLink>; i Siriraj Hospital , Mahidol University , Bangkok , Thailand.<br /><searchLink fieldCode="AU" term="%22Osmanov+E%22">Osmanov E</searchLink>; j Cancer Research Center RAMS - N.N. Blokhin Academy of Medical Science , Moscow , Russian Federation.<br /><searchLink fieldCode="AU" term="%22Pereira+J%22">Pereira J</searchLink>; k Hospital das Clinicas da Faculdade de Medicina da USP , São Paolo , Brazil.<br /><searchLink fieldCode="AU" term="%22Mayer+J%22">Mayer J</searchLink>; l Faculty Hospital Brno , Brno , Czech Republic.<br /><searchLink fieldCode="AU" term="%22Hong+X%22">Hong X</searchLink>; m Fudan University Shanghai Cancer Center , Shanghai , China.<br /><searchLink fieldCode="AU" term="%22Okamoto+R%22">Okamoto R</searchLink>; n Department of Chemotherapy , Tokyo Metropolitan Cancer and Infectious Diseases Center , Komagome Hospital , Japan.<br /><searchLink fieldCode="AU" term="%22Pei+L%22">Pei L</searchLink>; o Janssen Research and Development, LLC , Raritan , NJ , USA.<br /><searchLink fieldCode="AU" term="%22Rooney+B%22">Rooney B</searchLink>; p Janssen Research & Development , High Wycombe , Buckinghamshire , UK.<br /><searchLink fieldCode="AU" term="%22van+de+Velde+H%22">van de Velde H</searchLink>; q Millennium Pharmaceuticals, Inc. , Cambridge , MA , USA , a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.<br /><searchLink fieldCode="AU" term="%22Cavalli+F%22">Cavalli F</searchLink>; r Oncology Institute of Southern Switzerland, Ospedale San Giovanni , Bellinzona , Ticino , Switzerland.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229007422%22">Leukemia & lymphoma</searchLink> [Leuk Lymphoma] 2019 Jan; Vol. 60 (1), pp. 172-179. <i>Date of Electronic Publication: </i>2017 Jun 05.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9007422 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1029-2403 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210268022%22">10268022 </searchLink><i>NLM ISO Abbreviation: </i>Leuk Lymphoma <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=28583031
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/10428194.2017.1321750
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 172
    Titles:
      – TitleFull: Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Robak T
      – PersonEntity:
          Name:
            NameFull: Huang H
      – PersonEntity:
          Name:
            NameFull: Jin J
      – PersonEntity:
          Name:
            NameFull: Zhu J
      – PersonEntity:
          Name:
            NameFull: Liu T
      – PersonEntity:
          Name:
            NameFull: Samoilova O
      – PersonEntity:
          Name:
            NameFull: Pylypenko H
      – PersonEntity:
          Name:
            NameFull: Verhoef G
      – PersonEntity:
          Name:
            NameFull: Siritanaratkul N
      – PersonEntity:
          Name:
            NameFull: Osmanov E
      – PersonEntity:
          Name:
            NameFull: Pereira J
      – PersonEntity:
          Name:
            NameFull: Mayer J
      – PersonEntity:
          Name:
            NameFull: Hong X
      – PersonEntity:
          Name:
            NameFull: Okamoto R
      – PersonEntity:
          Name:
            NameFull: Pei L
      – PersonEntity:
          Name:
            NameFull: Rooney B
      – PersonEntity:
          Name:
            NameFull: van de Velde H
      – PersonEntity:
          Name:
            NameFull: Cavalli F
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: 2019 Jan
              Type: published
              Y: 2019
          Identifiers:
            – Type: issn-electronic
              Value: 1029-2403
          Numbering:
            – Type: volume
              Value: 60
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Leukemia & lymphoma
              Type: main
ResultId 1